Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Hits Estimates

Cytokinetics (NASDAQ:CYTK) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts’ consensus estimates of ($1.67), FiscalAI reports. The company had revenue of $19.36 million for the quarter, compared to analyst estimates of $8.52 million. The firm’s revenue for the quarter was up 1112.5% on a year-over-year basis. During the same period last year, the firm earned ($1.36) earnings per share.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO U.S. launch exceeded expectations in a partial quarter with $4.8M net product revenue, ~680 patients prescribed by quarter-end (1,100 through April), and >275 unique HCP prescribers, supporting early commercial momentum.
• Top-line results from ACACIA‑HCM (aficamten) met both co‑primary endpoints (KCCQ and peak VO2) with statistically significant treatment effects and no new safety signals, prompting plans to engage regulators and pursue a supplemental NDA for NHCM.
• Q1 net loss widened to $206M (vs. $161M year‑ago), cash and investments declined to ~$1.1B after ~$144M use in the quarter, and SG&A rose to $104.9M due to commercial launch costs, though full‑year expense guidance was maintained.
• Rapid global commercialization and regulatory progress — EU approval with a Germany launch planned in Q2, FDA acceptance of the MAPLE‑HCM sNDA (PDUFA 11/14/2026), plus ongoing MAA submissions (Switzerland, Canada) and partner progress in APAC — support international growth plans.

Cytokinetics Stock Up 16.7%

Shares of NASDAQ CYTK traded up $11.04 during trading hours on Tuesday, hitting $77.09. The company had a trading volume of 18,074,833 shares, compared to its average volume of 1,670,310. The stock has a market capitalization of $9.58 billion, a P/E ratio of -11.81 and a beta of 0.38. The firm’s 50 day moving average is $64.00 and its 200-day moving average is $63.63. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $80.20.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline Phase‑3 win — the ACACIA‑HCM pivotal trial of aficamten met both dual primary endpoints with supportive secondary data, a major de‑risking event that expands the drug’s commercial and regulatory potential. ACACIA‑HCM Topline Results
• Positive Sentiment: Strong initial commercial uptake — management reported U.S. launch demand for MYQORZO with ~275 HCPs prescribing to an estimated ~680 patients in Q1 and ~$4.8M in partial‑quarter net product revenue; company also reported ~ $1.1B in cash, which supports launch and development. Q1 2026 Financial Results & Business Update
• Positive Sentiment: Analyst upgrades — Needham (and other firms) raised price targets, increasing buy‑side enthusiasm and providing upward analyst momentum for shares. Analyst Price Target Raises
• Neutral Sentiment: Q1 reported EPS loss of ($1.67) matched expectations while revenue materially beat consensus ($19.36M vs ~$8.5M), signaling revenue strength but continued GAAP losses as the company scales launch and development. Q1 Loss, Revenue Beat
• Neutral Sentiment: Insider sales disclosed — EVP Andrew Callos and EVP Fady Malik sold shares under pre‑arranged Rule 10b5‑1 plans (large planned disposals rather than ad‑hoc exits); commonly viewed as neutral but can prompt short‑term investor attention. Malik SEC Form 4 Callos SEC Form 4
• Negative Sentiment: Planned $650M underwritten common stock offering — while proceeds would fund commercialization and development, the offering presents near‑term dilution risk that can weigh on the share price until completed. Proposed Public Offering

Insider Buying and Selling

In other news, CEO Robert I. Blum sold 36,601 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $2,274,752.15. Following the completion of the transaction, the chief executive officer directly owned 430,330 shares in the company, valued at approximately $26,745,009.50. The trade was a 7.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew Callos sold 26,000 shares of Cytokinetics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $61.87, for a total value of $1,608,620.00. Following the completion of the transaction, the executive vice president owned 50,440 shares in the company, valued at approximately $3,120,722.80. This represents a 34.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 184,976 shares of company stock valued at $11,639,319. 2.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently bought and sold shares of CYTK. Persistent Asset Partners Ltd acquired a new position in Cytokinetics in the 4th quarter worth about $204,000. CIBC Asset Management Inc acquired a new stake in shares of Cytokinetics during the fourth quarter valued at about $203,000. CIBC Private Wealth Group LLC boosted its stake in shares of Cytokinetics by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 261 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Cytokinetics by 408.8% during the third quarter. Larson Financial Group LLC now owns 1,852 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 1,488 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Cytokinetics by 218.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,458 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 1,000 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on CYTK shares. Mizuho lifted their price target on shares of Cytokinetics from $84.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 18th. Barclays increased their price target on Cytokinetics from $87.00 to $95.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Royal Bank Of Canada increased their target price on Cytokinetics from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Wells Fargo & Company initiated coverage on shares of Cytokinetics in a report on Friday, April 10th. They issued an “overweight” rating and a $95.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cytokinetics from $74.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.10.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.